Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer

Figure 2

Survival outcomes according to the CA9 expression scores. The median PFS was 3.9 months and median OS with bevacizumab was 11.4 months; after the 17.6 months of median follow up of all 31 patients. There were statistically significant differences between the 2 groups according to the score in terms of median PFS (4.7 mo vs. 2.4 mo, p = 0.028) and median OS (24.1 mo vs. 10.2 mo, p = 0.026).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us